Endothelial cell recovery, acute thrombogenicity, and monocyte adhesion and activation on fluorinated copolymer and phosphorylcholine polymer stent coatings.
This study compares the effects of two polymers currently being marketed on commercially available drug-eluting stents, PVDF-HFP fluorinated copolymer (FP) and phosphorylcholine polymer (PC), on re-endothelialization, acute thrombogenicity, and monocyte adhesion and activity. Rabbit iliac arteries were implanted with cobalt-chromium stents coated with FP or PC polymer (without drug) and assessed for endothelialization at 14 days by confocal and scanning electron microscopy (SEM). Endothelialization was equivalent and near complete for FP and PC polymer-coated stents (>80% by SEM). Acute thrombogenicity was assessed in a Chandler loop model using porcine blood. Thrombus adherence was similar for both polymers as assessed by clot weight, thrombin-antithrombin III complex, and lactate dehydrogenase expression. In vitro cell adhesion assays were performed on FP and PC polymer-coated glass coupon surfaces using HUVECs, HCAECs, and THP-1 monocytes. The number of ECs adhered to FP and control surfaces were equivalent and significantly greater than on PC surfaces (p<0.05). There were no differences in THP-1 monocyte adhesion and cytokine (MCP-1, RANTES, IL-6, MIP-1alpha, MIP-1beta, G-CSF) expression. The data suggests that biological responses to both FP and PC polymer are similar, with no mechanistic indication that these polymers would be causative factors for delayed vessel healing in an acute timeframe.
Chin-Quee
Shawn L
SL
Abbott Vascular, Santa Clara, CA 95054, USA. shawn.chinquee@av.abbott.com
Hsu
Steve H
SH
Nguyen-Ehrenreich
Kim L
KL
Tai
Julie T
JT
Abraham
George M
GM
Pacetti
Stephen D
SD
Chan
Yen F
YF
Nakazawa
Gaku
G
Kolodgie
Frank D
FD
Virmani
Renu
R
Ding
Nadine N
NN
Coleman
Leslie A
LA
D000818:Animals; D002448:Cell Adhesion / Q000187:drug effects; D002460:Cell Line; D018932:Chemokine CCL2 / Q000378:metabolism; D054405:Chemokine CCL3 / Q000378:metabolism; D054407:Chemokine CCL4 / Q000378:metabolism; D018946:Chemokine CCL5 / Q000378:metabolism; D054855:Drug-Eluting Stents / Q000009:adverse effects; D042783:Endothelial Cells / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism / Q000648:ultrastructure; D005465:Fluorocarbon Polymers / Q000737:chemistry / Q000494:pharmacology; D016179:Granulocyte Colony-Stimulating Factor / Q000378:metabolism; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism; D008297:Male; D008855:Microscopy, Electron, Scanning; D009000:Monocytes / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D010767:Phosphorylcholine / Q000737:chemistry / Q000494:pharmacology; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000378:metabolism; D011108:Polymers / Q000737:chemistry*; D011817:Rabbits; D018180:Thrombomodulin / Q000378:metabolism; D013927:Thrombosis / Q000139:chemically induced*
D018932:Chemokine CCL2; D054405:Chemokine CCL3; D054407:Chemokine CCL4; D018946:Chemokine CCL5; D005465:Fluorocarbon Polymers; D015850:Interleukin-6; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D011108:Polymers; D018180:Thrombomodulin; D010767:Phosphorylcholine; D016179:Granulocyte Colony-Stimulating Factor